J&J: licensing agreement with Korea's LegoChem in ADCs
December 27, 2023 at 10:44 am
Share
LegoChem Biosciences announced yesterday the conclusion of an exclusive licensing agreement with Janssen Biotech, under which the South Korean laboratory will grant the J&J subsidiary the rights to one of its conjugated antibodies (CDAs).
Under the terms of the agreement, Innate has received an upfront payment of $100 million, and will be entitled to receive up to a further $200 million if the option for LCB84 is exercised.
Taking into account development, regulatory and commercial milestone payments, LegoChem estimates that it could receive total royalties of $1.7 billion on potential sales of the product.
LCB84, currently in Phase 1/2 clinical trials in the U.S., features a differentiated mechanism of action, as it targets the Trop2 antigen, highly expressed in cancer cells.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows:
- pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
- consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc.
At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25).
Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).